An in vitro study proved that TSLP and T cell-derived CD40L synergy contribute to DC maturation and subsequent IL-23 production by skin DCs and primary blood obtained from patients with PVs, which can be inhibited by a specific type 2 immune cytokine IL-4 in a dose-dependent manner (70). This evidence concerns the gene IL23A and perivascular space measurement.